Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent

Journal of Clinical Microbiology

Volumn 52, Issue 7, 2014, Pages 2629-2632

  Ross, James E ^a   Scangarella Oman, Nicole E ^b   Flamm, Robert K ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b GLAXOSMITHKLINE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; GSK 2140944; GYRASE INHIBITOR; UNCLASSIFIED DRUG; DNA TOPOISOMERASE INHIBITOR;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CLINICAL LABORATORY; CONTROLLED STUDY; DISK DIFFUSION; DRUG STRUCTURE; ESCHERICHIA COLI; GOOD MANUFACTURING PRACTICE; HAEMOPHILUS INFLUENZAE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL PROCEDURES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; CHEMICAL STRUCTURE; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MICROBIAL SENSITIVITY TEST; QUALITY CONTROL; STANDARDS;

ANTI-INFECTIVE AGENTS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; QUALITY CONTROL; TOPOISOMERASE INHIBITORS;

EID: 84903762701     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00656-14     Document Type: Article

References (7)

1. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935-940. http://dx.doi.org/10. 1038/nature09197.
2. Bouchillon S, Hackel M, Miller LA, Scangarella-Oman NE. 2013. In vitro activity of GSK2140944, a novel topoisomerase inhibitor, against isolates associated with lower respiratory tract and skin infections, abstr F-1216. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., Denver, CO, 10 to 13 September, 2013.
3. Clinical and Laboratory Standards Institute. 2008. M23-A3. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, 3rd ed. CLSI document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial disk susceptibility tests; approved standard-11th ed. CLSI document M02-A11. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Turnidge J, Bordash G. 2007. Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing. Antimicrob. Agents Chemother. 51:2483-2488. http://dx.doi.org/10.1128/AAC.01457-06. (Pubitemid 47047327)